A method for imaging a brain of a subject includes providing a cognitive task for the subject or measuring resting state blood flow without a cognitive task,...
A method for imaging a brain of a subject includes providing a cognitive task for the subject or measuring resting state blood flow without a cognitive task, applying a saturation pulse sequence to saturate a slice within an imaging volume in the subject, and applying an imaging pulse sequence to acquire data from the imaging volume.
A saturated image is acquired shortly after termination of the saturation pulse sequence and a non-saturation image is acquired after spins flowing through the saturated slice have recovered. The saturation image and the non-saturation image are subtracted to generate a blood velocity or perfusion enhanced difference image indicating portions of the brain active during the cognitive task.
When measuring resting state blood flow without a cognitive task, the method includes acquiring a calibration scan and performing a quantitative evaluation of the blood velocity perpendicular to the saturated slice.
Although there are already a few existing compounds for use in the treatment of bone diseases, these new compounds may have efficacy exceeding that of current...
Although there are already a few existing compounds for use in the treatment of bone diseases, these new compounds may have efficacy exceeding that of current commercial species. In some cases, existing treatments have high toxicity and low efficacy. These new compounds may, therefore, be better than existing therapeutic options.
These new compounds can help restore the natural balance between normal bone destruction and replacement. They are also potential candidates for the treatment of cancer and infectious diseases as related compounds have been shown to kill tumor cells and parasites. They have been shown to stimulate T-Cells, assisting in the treatment of cancer and infectious diseases.
They have multiple targets, some involved in regulating apoptosis, and displays increased potency, making it a possible cancer drug. Its improved cell availability lowers the effective dose and can lead to fewer side effects.
These compounds make up a series of bisphosphonates useful for the treatment of bone-related diseases, cancer and infections caused by protozoa and bacteria. The compounds represent new compositions of matter. Current clinical Bisphosphonates contain a nitrogen atom that can be positively charged. The new compounds have positively charged P, As, Sb, S, Se or Te sites instead of nitrogen. They may have higher activity in treating a variety of diseases than existing compounds and may have lower toxicity than existing compounds.
Professor Timothy Bretl of the Aerospace Engineering and Navid Aghasadeghi of ECE both from the University of Illinois have developed a method for learning...
Professor Timothy Bretl of the Aerospace Engineering and Navid Aghasadeghi of ECE both from the University of Illinois have developed a method for learning controller parameters for lower-limb prostheses using only observed unimpaired trajectories and the physical characteristics of amputees.
This technique is an improvement over the usual trial and error method that is currently used in the fitting of lower-limb prosthetic devices.
Patient characteristics are applied in an algorithm to automatically learn controller parameters for level-walking at a desired cadence, stair/ramp ascent and other modes of locomotion.
Below the knee muscle weakness, defined by weak dorsiflexor (shin) or plantarflexor (calf) muscle groups, can result from a variety of physical impairments or...
Below the knee muscle weakness, defined by weak dorsiflexor (shin) or plantarflexor (calf) muscle groups, can result from a variety of physical impairments or congenital abnormalities. Stroke, spinal cord injuries, polio and multiple sclerosis are among some of the physical injuries and congenital defects responsible for the condition. The largest complication from below the knee muscle weakness is abnormal gait, which when compensated for can lead to further complications in other muscles and joints.
Ankle-foot-orthoses (AFOs) have been designed to assist afflicted individuals in walking and rehabilitation of the weakened muscle groups. Unfortunately, many commercially available AFOs are passive devices that cannot provide assistance during the propulsive phase of gait. Furthermore, these instruments are not capable of adapting to changes in walking conditions. Powered AFOs have been engineered to overcome these limitations but lack practicality in that they are commonly tethered to off-board power sources.
This technology provides a non-tethered, portable pneumatic powered AFO that controls and assists propulsion of the foot as well as ankle motion using plantarflexor and dorsiflexor torque at the ankle joint.
A custom-built pneumatic rotary actuator is located at the ankle joint. Torque generated by the actuator is used for both motion control of the foot and to provide supplemental torque for the individual during gait. Pressure regulators are used to manage the force produced by the rotary actuator and valves are used to direct the flow of fluid power to the actuator. Control and sensing of the actuator is accomplished through use of pressure and angle sensors and onboard electronics.
This device can be used to aid individuals afflicted with below the knee muscle weakness or impaired gait resulting from any number of physical injuries or congenital disabilities. Portability of the device permits the device to be used in a variety of locations. Applications include:
The portable pneumatic AFO is beneficial compared to passive AFOs in that it:
Benefits over other powered AFOs include: